FIELD: medicine.
SUBSTANCE: level of gene expression: MGB1, Ki67, Aurca, BIRC5, CCNB1, MMP11 is determined in the breast tissue and if the level of expression for the above-mentioned genes exceeds, respectively: 13120.05; 21.1; 52.54; 15.96; 13.89; 18.51, the malignant nature of the process is concluded, and tissue biopsy is recommended for morphological confirmation and/or specific treatment.
EFFECT: obtaining of conclusion on the malignant nature of breast tissue and an ability to recommend repeated biopsy or specific treatment.
2 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSING BREAST CANCER AND OVARIAN CANCER BY MMP-9 MRNA LEVEL IN BLOOD PLASMA | 2020 |
|
RU2745424C1 |
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF MRNA TGEβ AND TNFα IN BLOOD PLASMA | 2019 |
|
RU2742209C1 |
| METHOD FOR DETERMINING THE PROGNOSIS OF THE EFFECTIVENESS OF BREAST CANCER THERAPY | 2021 |
|
RU2757590C1 |
| METHOD FOR PREDICTING DEVELOPMENT OF METASTASES IN PATIENTS WITH BREAST CANCER | 2018 |
|
RU2675236C1 |
| METHOD FOR PERSONALIZED ASSIGNMENT OF NEOAJUVANT CHEMOTHERAPY TO PATIENTS SUFFERING FROM LUMINAL TYPE B BREAST CANCER | 2015 |
|
RU2594251C1 |
| METHOD FOR ASSESSING THE RISK OF PROGRESSION OF INTRAEPITHELIAL CERVICAL NEOPLASIA AND DEVELOPMENT OF CERVICAL CANCER BY DETERMINING THE LEVELS OF HUMAN MRNA GENES | 2015 |
|
RU2660360C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSTICS OF FIBROADENOMA AND BREAST CANCER | 2020 |
|
RU2730993C2 |
| METHOD FOR DIAGNOSING BREAST CANCER BY THE LEVEL OF METHYLATION OF THE ZNF177 AND CCDC181 GENES IN SMALL TUMORS | 2022 |
|
RU2789200C1 |
| METHOD OF DETERMINING PROBABILITY OF RECURRENT BREAST CANCER | 2014 |
|
RU2609199C2 |
| DIAGNOSTIC TECHNIQUE FOR HYPERPROLIFERATIVE CONDITIONS AND METHOD FOR ASSESSING RISK OF CERVICAL CANCER ACCOMPANYING CERVICAL INTRAEPITHELIAL NEOPLASIA AND PAPILLOMA VIRUS CARRIER STATE BY DETERMINIG MRNA OF FUNCTIONAL HUMAN GENE COMPLEX | 2012 |
|
RU2532344C2 |
